GUANGJI PHARMA.(SZ:000952) Shang Hai Zheng Quan Bao·2025-09-18 20:01Group 1 - The core point of the announcement is the successful convening of the third extraordinary general meeting of shareholders of Hubei Guangji Pharmaceutical Co., Ltd., where all proposals were approved without any objections [1][2]. - The meeting was held on September 18, 2025, with a combination of on-site and online voting, ensuring broad participation from shareholders [3][5][6]. - A total of 87 participants representing 104,743,265 shares attended the meeting, accounting for 30.2071% of the total shares of the company [8]. Group 2 - The meeting approved three key proposals: the change of registered capital and revision of the company's articles of association, the revision of the rules for shareholder meetings, and the revision of the rules for board meetings [10][11][14]. - The voting results for the proposal on changing registered capital showed 99.3705% approval from the attending shareholders, with only 0.6152% opposed [10]. - The legal opinion provided by Hubei Zhongqin Law Firm confirmed that the meeting's procedures and resolutions were in compliance with relevant laws and regulations, validating the legality of the decisions made [18]. Group 3 - Hubei Guangji Pharmaceutical Co., Ltd. announced the receipt of a re-registration approval notice for the chemical raw material drug Vitamin B6 from the Hubei Provincial Drug Administration [21]. - The re-registration ensures the stability and continuity of the production and sales qualifications for Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [21][22]. - The approval notice is valid until September 16, 2030, indicating a long-term assurance for the company's operations in this segment [21].